Clinical Trial Update: Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of MNPR-101-PCTA-177Lu in solid tumors is currently recruiting across multiple cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Colorectal Cancer
• Gastric Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• MNPR-101-PCTA-177Lu

Snippet

Sponsor: Monopar Therapeutics | Conditions: Solid Tumor, Adult, Bladder Cancer | Phase 1 | Status: RECRUITING